About Alexion
Alexion is a company based in Zurich (Switzerland) founded in 1992 was acquired by Astrazeneca in December 2020.. Alexion has raised $8 million across 12 funding rounds from investors including Astrazeneca, Permira and HHS. The company has 2 employees as of March 22, 2024. Alexion has completed 8 acquisitions, including Achillion, Enobia Pharma and LogicBio. Alexion operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Zurich, Switzerland
- Employees 2 as on 22 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alexion Business Services Private Limited
- Date of Incorporation 03 Jun, 2011
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$293.75 K (USD)-59.48as on Mar 31, 2020
-
Net Profit
$49.59 K (USD)53.84as on Mar 31, 2020
-
EBITDA
$67.83 K (USD)38.68as on Mar 31, 2020
-
Total Equity Funding
$8 M (USD)
in 12 rounds
-
Latest Funding Round
$3.61 B (USD), Debt – Conventional
Jun 15, 2018
-
Investors
Astrazeneca
& 7 more
-
Employee Count
2
as on Mar 22, 2024
-
Investments & Acquisitions
Achillion
& 7 more
-
Acquired by
Astrazeneca
(Dec 12, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Leadership Team
54 people
Human Resources and Administration
25 people
Sales and Marketing
18 people
Finance and Accounting
16 people
Software Development Team
11 people
Product Management Team
10 people
Regional Team
9 people
Head Team
6 people
Unlock access to complete
Funding Insights of Alexion
Alexion has successfully raised a total of $8M across 12 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $3.61 billion completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Debt – Conventional — $3.6B
-
First Round
First Round
(29 Jun 1993)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2018 | Amount | Debt – Conventional - Alexion | Valuation |
investors |
|
| Jun, 2016 | Amount | Post-IPO - Alexion | Valuation |
investors |
|
| Jan, 2014 | Amount | Post-IPO - Alexion | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Alexion
Alexion has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Permira and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in Asia and Europe
|
Founded Year | Domain | Location | |
|
Investments are made in technology, consumer, healthcare, and service sectors.
|
Founded Year | Domain | Location | |
|
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Alexion
Alexion has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Achillion, Enobia Pharma and LogicBio. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Viral vectors are developed for genetic and infectious disease treatments.
|
2013 | ||||
|
IgG-mediated autoimmune diseases are treated via Fc receptor-targeting antibodies.
|
2013 | ||||
|
De-coppering agents for Wilson disease treatment are developed.
|
2012 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Alexion
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Alexion Comparisons
Competitors of Alexion
Alexion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Alexion
Frequently Asked Questions about Alexion
When was Alexion founded?
Alexion was founded in 1992 and raised its 1st funding round 1 year after it was founded.
Where is Alexion located?
Alexion is headquartered in Zurich, Switzerland.
Who is the current CEO of Alexion?
Ludwig Hantson is the current CEO of Alexion.
Is Alexion a funded company?
Alexion is a funded company, having raised a total of $8M across 12 funding rounds to date. The company's 1st funding round was a Post-IPO of $25M, raised on Jun 29, 1993.
How many employees does Alexion have?
As of Mar 22, 2024, the latest employee count at Alexion is 2.
What is the annual revenue of Alexion?
Annual revenue of Alexion is $293.75K as on Mar 31, 2020.
What does Alexion do?
Alexion was founded in 1992 and is based in Zurich, Switzerland. Focus is placed on developing treatments for rare diseases affecting hematology, nephrology, neurology, metabolic, and cardiology areas. Soliris, a terminal complement inhibitor, is utilized for myasthenia gravis management, and Ultomiris addresses hemolytic uremic syndrome. Operations center on pharmaceutical innovation for underserved patient populations in these medical fields.
Who are the top competitors of Alexion?
Alexion's top competitors include Moderna, Spark Therapeutics and BridgeBio.
How many acquisitions has Alexion made?
Alexion has made 8 acquisitions, including Achillion, Enobia Pharma, and LogicBio.
Who are Alexion's investors?
Alexion has 8 investors. Key investors include Astrazeneca, Permira, HHS, Allen & Company, and BB Biotech.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.